Treat FTD Fund
Forecasted
The Treat FTD Fund from the Alzheimer's Drug Discovery Foundation supports early-stage research and clinical trials to develop new therapies and biomarkers for frontotemporal degeneration.
Browse similar grants
Funder: Alzheimer's Drug Discovery Foundation
Due Dates (Anticipated): November 2026 (Letter of Intent) | February 2027 (Full proposal, invited)
Funding Amounts: Up to $2,500,000 over 1–3 years; typical awards range from $500,000–$2,000,000.
Summary: Supports early-stage clinical trials and research to advance new therapies and biomarkers for frontotemporal degeneration (FTD).
Description
The Treat FTD Fund is a collaborative initiative by the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) aimed at accelerating early-stage clinical trials for frontotemporal degeneration (FTD) disorders. The fund supports research that advances understanding of FTD pathophysiology, explores new or repurposed therapeutics, and develops validated biomarkers and innovative trial methodologies. Projects should emphasize biologically informed trial designs and patient-centric outcome measures, with the goal of developing both disease-modifying and symptomatic therapies for FTD, a field with significant unmet medical need.
